2023-10-05T04:46:27+03:00[Europe/Moscow] en true <p>smoking cessation/quit date, proper inhaler technique, pulmonary rehabilitation, vaccines, oxygen therapy</p>, <p>symptomatic people with hx of frequent/ severe exacerbations </p>, <p>smoking cessation, pulmonary rehab, long-term O2, noninvasive positive pressure ventilation, lung volume reduction surgery</p>, <p>COVID-19, flu, pneumococcal, tdap, zoster </p>, <p>PCV20; PCV15; PPSV23</p>, <p>false </p>, <p>&gt;1; SABAs</p>, <p>b</p>, <p>LABAs &amp; LAMAs</p>, <p>a</p>, <p>improves lung function; decreases dyspnea/exacerbations</p>, <p>LAMAs; LABAs</p>, <p>blood eosinophil count </p>, <p>history of hospitalizations, &gt;=2 moderate exacerbations per year, blood eosinophil &gt;=300, history of asthma </p>, <p>repeated pneumonia events, blood eosinophils &lt; 100, history of mycobacterial infection</p>, <p>severe/very severe COPD (Gold 3 &amp;4) + history of exacerbation </p>, <p>after hospitalization </p>, <p>warfarin, digoxin </p>, <p>dose-related</p>, <p>b,c </p>, <p>a</p>, <p>b,c</p>, <p>60-90 days</p>, <p>pneumonia, pulmonary embolism, HF</p>, <p>bronchodilators, corticosteroids, antibiotics </p>, <p>group E; blood eos &gt;=300</p>, <p>different MOA, increases bronchodilation, improves FEV1/symptoms </p>, <p>budesonide, albuterol, ipratropium + albuterol, formoterol </p>, <p>b</p>, <p> occasional dyspnea</p>, <p>an ICS</p>, <p>PaO2 &lt;=55-60mmHg; cor pulmonale or secondary polycythemia </p>, <p>hospitalized for exacerbation during/within &lt;=4 weeks of discharge</p>, <p>stable COPD w marked hypercapnia </p>, <p>upper lope emphysema + low exercise capacity </p>, <p>Longterm O2 therapy </p>, <p>tremors, tachycardia, hypokalemia, hyperglycemia </p>, <p>increase side effects; hyper-responsiveness</p>, <p>bitter, metallic taste, upper RT infection, constipation, blurred vision (sprayed in eyes) </p>, <p>increases risk of exacerbation </p> flashcards
COPD therapeutics PT.2 (Diagnosis/Initial Assessment)

COPD therapeutics PT.2 (Diagnosis/Initial Assessment)

  • smoking cessation/quit date, proper inhaler technique, pulmonary rehabilitation, vaccines, oxygen therapy

    What should we address at every appointment? (5)

  • symptomatic people with hx of frequent/ severe exacerbations

    Trelegy Ellipta has been proven to lower mortality in which patients?

  • smoking cessation, pulmonary rehab, long-term O2, noninvasive positive pressure ventilation, lung volume reduction surgery

    Which non-pharmacological treatments have been proven to lower

    mortality? (5)

  • COVID-19, flu, pneumococcal, tdap, zoster

    Which vaccines do we recommend for COPD patients?(5)

  • PCV20; PCV15; PPSV23

    The CDC recommends one dose of _______; or one dose of _______

    followed by one dose of ________.

  • false

    Integrative care and Telehealth have demonstrated benefits in reducing exacerbations. T/F?

  • >1; SABAs

    _______ canisters a month of ______ suggest inadequate control of COPD.

  • b

    Which are the MOST effective for relief of acute bronchospasms?

    a) LABAs

    b) SABAs

    c) SAMAs

    d) LABA+ LAMA

    e) LAMA

  • LABAs & LAMAs

    __________ can be used alone in COPD.

  • a

    Which can cause QTc prolongation?

    a) LABAs

    b) SABAs

    c) SAMAs

    d) LABA+ LAMA

    e) LAMA

  • improves lung function; decreases dyspnea/exacerbations

    What are the benefits of Antimuscarinics? (2)

  • LAMAs; LABAs

    _______ have a greater effect on exacerbation & hospital reductions than _______.

  • blood eosinophil count

    How can we predict the magnitude of the effect when using ICS?

  • history of hospitalizations, >=2 moderate exacerbations per year, blood eosinophil >=300, history of asthma

    When do we STRONGLY FAVOR the use of an ICS to a patient's therapy? (4)

  • repeated pneumonia events, blood eosinophils < 100, history of mycobacterial infection

    When are we AGAINST the use of an ICS? (3)

  • severe/very severe COPD (Gold 3 &4) + history of exacerbation

    Roflumilast is indicated for which patients? (2)

  • after hospitalization

    When is the most beneficial time to give a patient Roflumilast?

  • warfarin, digoxin

    What medications interact with Theophylline? (2)

  • dose-related

    Theophylline has a ________ toxicity.

  • b,c

    Which patient Groups should receive a LABA + LAMA for initial treatment?

    a) Group A

    b) Group B

    c) Group E

  • a

    Which groups receive a bronchodilator?

    a) Group A

    b) Group B

    c) Group E

  • b,c

    Which group receives smoking cessation + pulmonary rehab?

    a) Group A

    b) Group B

    c) Group E

  • 60-90 days

    When do we recheck patient's oxygen levels?

  • pneumonia, pulmonary embolism, HF

    What are the most common causes of COPD exacerbations? (3)

  • bronchodilators, corticosteroids, antibiotics

    The most common medications used in COPD exacerbations? (3)

  • group E; blood eos >=300

    When can we consider starting a patient on LABA + LAMA + ICS? (2)

  • different MOA, increases bronchodilation, improves FEV1/symptoms

    What are the benefits of using a LABA + LAMA? (3)

  • budesonide, albuterol, ipratropium + albuterol, formoterol

    Which medications are available in nebulizers? (4)

  • b

    Trelegy Ellipta is a ______ inhaler.

    a) soft-mist

    b) DPI

    c) MDI

    d) twist

  • occasional dyspnea

    Short-acting agents are preferred in patients with _________

  • an ICS

    In patients with COPD + features with asthma, their treatment should

    ALWAYS contain what?

  • PaO2 <=55-60mmHg; cor pulmonale or secondary polycythemia

    Long-term O2 therapy improves mortality in which patients? (2)

  • hospitalized for exacerbation during/within <=4 weeks of discharge

    Pulmonary rehabilitation improves mortality in which patients?

  • stable COPD w marked hypercapnia

    Noninvasive positive pressure ventilation improves mortality in which patients?

  • upper lope emphysema + low exercise capacity

    Lung volume reduction surgery improves mortality in which patients?

  • Longterm O2 therapy

    __________ is NOT recommended in stable COPD.

  • tremors, tachycardia, hypokalemia, hyperglycemia

    AE's of SABAs? (4)

  • increase side effects; hyper-responsiveness

    Regularly scheduled use of SABAs can _________ & cause __________.

  • bitter, metallic taste, upper RT infection, constipation, blurred vision (sprayed in eyes)

    AE's of Antimuscarinics (4)

  • increases risk of exacerbation

    What happens in a patient w COPD + Blood eos >=300 that suddenly

    discontinues their ICS?